S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.
Elihu H. Estey,Zhuoxin Sun,Jacob M. Rowe,Stefan Faderl,Peter A. Cassileth,George Sartiano,Anthony Tartaglia,Guillermo Garcia-Manero,Larry D. Cripe,John M. Bennett,Hagop M. Kantarjian,Martin S. Tallman +11 more
TL;DR: The data indicate that in older pts given ara-C-containing regimens, long-term survival is essentially impossible without achievement of CR, and it appears likely that newer “targeted agents” will have to contribute more than producing responses.
Journal ArticleDOI
Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy
Farhad Ravandi,Deepa Sampath,William Plunkett,Betsy Williams,Michelle Burton,Srdan Verstovsek,Stefan Faderl,Guillermo Garcia-Manero,Vernon Alvarez,Michael D Becker,Alan F. List,Said M. Sebti,Hagop M. Kantarjian,Jeffrey E. Lancet +13 more
TL;DR: Results of a phase I dose-escalation clinical and pharmacodynamic study of TCN-PM in patients with advanced hematological malignancy indicate an inhibition of this survival pathway and activity of triciribine in this patient population.
Journal ArticleDOI
Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)
Preetesh Jain,Hagop M. Kantarjian,Deborah A. Thomas,Farhad Ravandi,Tapan M. Kadia,Jan A. Burger,Gautam Borthakur,Jorge E. Cortes,Naval Daver,Elias Jabbour,Charles Koller,Marina Konopleva,Naveen Pemmaraju,Marry A Kelly,Rebecca Garris,Susan O'Brien,Stefan Faderl +16 more
TL;DR: Three patients with Ph+ALL underwent alloSCT without MMR without MMR who obtained CMR with 2nd generation TKIs showed a prompt response to 2-TKIs treatment that can rescue Ph+ ALL patients after SCT failure.
Journal ArticleDOI
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome
Gail J. Roboz,H. Jean Khoury,Elias Jabbour,Wilena Session,Ellen K. Ritchie,Harry Miao,Stefan Faderl,Wei Zheng,Eric J. Feldman,Martha Arellano,J. Gilmour Morrison,Farhad Ravandi +11 more
TL;DR: A phase I dose escalation trial of SAR103168, a novel multi-targeted kinase inhibitor with activity against the Src kinase family, the BCR–Abl kinase and several angiogenic receptor kinases is conducted.
Journal ArticleDOI
Preliminary Results of Fixed-Dose Oral Clofarabine (CLO) In Patients Who Have Failed Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes (MDS)
Mikkael A. Sekeres,Gail J. Roboz,Olatoyosi Odenike,Edward Agura,Bayard L. Powell,Reginald Ewesuedo,Michael J. Vasconcelles,Stefan Faderl,Hagop M. Kantarjian +8 more
TL;DR: This is the first study designed to determine the appropriate dose, and to assess the efficacy and safety of oral clofarabine (CLO) specifically in higher-risk MDS or secondary acute myeloid leukemia (sAML) pts who failed treatment with a hypomethylating agent.